Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax®.
Flashworks received $200,000 through MLSC Milestone Achievement Program (MAP). MAP was designed to address the needs of early-stage life sciences companies by providing grant funding to execute critical, value-creating technical milestones.